News & Events

Media

NOV 19, 2024
LIB Therapeutics Announce Positive Results from Lerodalcibep 72-Week Open-Label Extension Studies at American Heart Association 2024
Read article
View PDF
MAY 29, 2024
LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress
Read article
View PDF
MAY 23, 2024
LIB Therapeutics Announces Lerodalcibep Abstracts Accepted for Presentation at the 92nd European Atherosclerosis Society Congress
Read article
View PDF
APR 8, 2024
LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024
Read article
View PDF
APR 3, 2024
LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference
Read article
View PDF
APR 1, 2024
LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024
Read article
View PDF
MAR 19, 2024
LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China
Read article
View PDF
feb 13, 2024
LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024
Read article
View PDF
DEC 7, 2023
LIB Therapeutics Announces Appointment of Ingrid Choong, PhD as Chief Business Officer as Company Prepares BLA for Lerodalcibep
Read article
View PDF
nov 14, 2023
LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease
Read article
View PDF
SEP 12, 2023
LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China
Read article
View PDF
sep 11, 2023
LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion
Read article
View PDF
AUG 28, 2023
LIB Therapeutics Announces Positive Results from the Phase 3 Long-term efficacy and safety of Lerodalcibep in heterozygous familial hypercholesterolemia (LIBerate-HeFH) trial.
Read article
View PDF
Phase 3 LIBerate OLE for FH - AHA 2024
NOV 18, 2024
View presentation
Phase 3 LIBerate OLE for CVD and HR/VHR CVD - AHA 2024
NOV 18, 2024
View presentation
Phase 3 LIBerate-CVD - EAS 2024
JUN 11, 2024
View presentation
LIBerate-VI (vs. Inclisiran) Poster - EAS 2024
JUN 11, 2024
View POSTER
Phase 3 LIBerate HeFH Open-Label Extension - ACC 2024
APR 8, 2024
View POSTER
Phase 3 LIBerate-HR (High Risk) Topline Data - ACC 2024
APR 8, 2024
View PDF
Phase 3 LIBerate HeFH Topline Data - ESC 2023
AUG 28, 2023
View PDF
Phase 3 LIBerate HoFH Topline Data - EAS 2023
may 21, 2023
View PDF
Phase 2b 52-Week Open-Label Extension Study - EAS 2020
oCT 5, 2020
View PDF
Phase 2 Dose-Finding Study - EAS 2019
May 27, 2019
View PDF
Phase 1 - ACC 2019
June 3, 2019
View PDF
Heading
This is some text inside of a div block.

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.